COLL Q1 2018 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$64M+2835.0% YoY

Gross Profit

$21M32.4% margin

Operating Income

-$13M-20.7% margin

Net Income

-$19M-29.3% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+490.6%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$11M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$696M

Total Liabilities

$605M

Stockholders' Equity

$91M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$2M	+2835.0%
Gross Profit	$21M	$2M	+1046.2%
Operating Income	-$13M	-$23M	+43.0%
Net Income	-$19M	-$23M	+19.2%

Revenue Segments

Nucynta

$48M75%

Xtampza

$16M25%